Zafgen to Present at Canaccord Genuity’s 36th Annual Growth Conference
August 03 2016 - 5:00PM
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated
to significantly improving the health and well-being of patients
affected by obesity and complex metabolic disorders, announced
today that Thomas Hughes, President and Chief Executive Officer of
Zafgen, will present at the upcoming Canaccord Genuity 36th Annual
Growth Conference in Boston on Wednesday, August 10, 2016 at 5:00
p.m. ET.
A live audio webcast and replay of the
presentation will be available through the Events and Presentations
page of the Investors section of the Company's website
(www.zafgen.com) for 90 days following the conclusion of the live
event.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical
company dedicated to significantly improving the health and
well-being of patients affected by obesity and complex metabolic
disorders. Zafgen is focused on developing novel therapeutics that
treat the underlying biological mechanisms of severe and
complicated obesity through the MetAP2 pathway. Zafgen has
pioneered the study of MetAP2 inhibitors in both common and rare
forms of obesity. Zafgen's lead product candidate is ZGN-1061,
which is a novel, first-in-class, twice-weekly subcutaneous
injection which is being developed for the treatment of severe and
complicated obesity. Zafgen is also developing ZGN-839, a
liver-targeted MetAP2 inhibitor, for the treatment of nonalcoholic
steatohepatitis, or NASH, and abdominal obesity. Zafgen aspires to
improve the lives of patients through targeted treatments and has
assembled a team accomplished in bringing therapies to patients
affected by metabolic diseases.
Investor Relations Contact:
Argot Partners
Investor Relations
Laura Perry or Glenn Garmont
212-600-1902
laura@argotpartners.com
glenn@argotpartners.com
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Apr 2023 to Apr 2024